KCT0009424尚未招募Unknown
A 8 weeks, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of SH003 of immunity function
Jaein R&P0 个研究点目标入组 120 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19(Year) 至 75(Year)（—）
- 性别
- All
入选标准
- •(1) Adult men and women aged 19 years or older and 75 years or less at the time of screening test
- •(2) Those who have had symptoms of upper respiratory infection (cold, tonsillitis, pharyngitis, laryngitis, sinusitis, otitis media, rhinitis, etc.) more than twice within 12 months before the screening test
- •(3) A person who, after hearing and fully understanding the detailed explanation of this clinical trial, voluntarily decides to participate and agrees in writing to comply with the precautions
排除标准
- •(1) WBC less than 3000 /ml or greater than 8000 /ml on screening test
- •(2) Immunizations (influenza, herpes zoster, pneumococcal, COVID-19, etc.) within 2 months prior to the date of first intake of the investigational product in humans
- •(3) BMI less than 18.5 kg/m2 or greater than 35 kg/m2 at the time of the screening test
- •(4) Taking medication for high blood pressure
- •(5) Have a thyroid condition
- •(6) Have medicated or uncontrolled diabetes (HbA1c > 7%)
- •(7) Have clinically significant acute or chronic cardiovascular, endocrine, immune, respiratory, hepatobiliary, renal and urinary, neuropsychiatric, musculoskeletal, inflammatory and hematologic/oncologic, or gastrointestinal disorders requiring medical treatment
- •(8) Those who have taken medicines or dietary supplements related to immune function within one month prior to the screening test
- •(9) Those with a history of significant hypersensitivity reactions to the ingredients
- •(10) Those who have been treated with antipsychotic medication within 3 months prior to the screening test
- •(11) Subjects with known or suspected alcoholism or drug abuse
- •(12) Participation in another human clinical trial within 3 months prior to the screening test
- •(13) Those with the following results in diagnostic medical tests
- •AST, ALT > 3 times the upper limit of the reference range
- •Serum Creatinine > 2.0 mg/dL
- •(14) Pregnant or lactating women
- •(15) Women of childbearing potential who are unwilling to accept adequate contraception
- •(16) Those deemed unsuitable for participation in the study by the principal investigator for other reasons, including the results of diagnostic medical tests.
研究者
相似试验
已完成
不适用
A human trial to evaluate the efficacy and safety of Echinacea extract on promotion of immunity enhancementKCT0006531Wonkwang University. Iksan Korean Medicine Hospital80
招募中
不适用
A 8 weeks, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Angelica gigas N. extract powder(Nutragen) on immune enhancementDiseases of the respiratory systemKCT0007832Jeonbuk National University Hospital100
招募中
不适用
the efficacy and safety of Triticum aestivum L. sprout extract on improvement of Liver functioDiseases of the digestive systemKCT0007271Woosuk University Korean Medicine Medical Center100
招募中
Unknown
A human trail of Saccaharum Officinalis L. wax alcohols(Policosanol) on improvement of blood cholesterolEndocrine, nutritional and metabolic diseasesKCT0008540Wonkwang University, Gwangju Medical Center100
招募中
不适用
APGP for the evaluation of efficacy on immune function and immune cell activatioKCT0002551Yonsei University100